Search Site

Search form

Current Press Releases

All Releases
View Summary ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jul 2, 2015
PDF 21.5 KB
View Summary FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jul 2, 2015
PDF 21.0 KB
View Summary Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors
Jun 18, 2015
PDF 8.6 KB
View Summary Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference
Jun 11, 2015
PDF 14.1 KB
View Summary Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Jun 4, 2015
PDF 16.5 KB
View Summary Vertex to Present at the Goldman Sachs Healthcare Conference on June 11
Jun 3, 2015
PDF 7.6 KB
View Summary New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
May 17, 2015
PDF 12.3 KB
View Summary Vertex to Present at the UBS Healthcare Conference on May 19
May 13, 2015
PDF 6.9 KB
View Summary Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation
May 12, 2015
PDF 11.3 KB
View Summary Vertex Reports First Quarter 2015 Financial Results
Apr 29, 2015
PDF 39.8 KB
View Summary Vertex to Announce First Quarter 2015 Financial Results on April 29
Apr 9, 2015
PDF 6.8 KB
View Summary Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Mar 23, 2015
PDF 27.6 KB
View Summary Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene
Mar 18, 2015
PDF 19.6 KB
View Summary Vertex to Present at Upcoming Investor Conferences
Feb 11, 2015
PDF 7.0 KB
View Summary Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015
Jan 28, 2015
PDF 58.5 KB
View Summary Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis
Jan 11, 2015
PDF 30.2 KB
View Summary Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results
Jan 6, 2015
PDF 7.2 KB
Showing 1-17 of 17 Page: 1